| Symbol | BLRX |
|---|---|
| Name | BIOLINE RX LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | BIOMED |
| Address | 2 HAMAAYAN STREET, MODIIN, 7177871, Israel |
| Telephone | 08-6429100 |
| Fax | 08-6429101 |
| info@biolinerx.com | |
| Website | www.biolinerx.com |
| Incorporation | Israel |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | TASE;NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001498403 |
| Description | BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates - Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions. Additional info from NASDAQ: |
BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
Read moreBioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026
Read moreFORM 6-K- Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
Read moreBioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model
Read moreBioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
Read moreBioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
Read moreBioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Read moreBioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Read more